Emma Lewisham utilises live skin probiotic to develop acne serum ‘without compromises’

By Amanda Lim

- Last updated on GMT

Emma Lewisham has developed what it claims to be the world-first acne serum with a live probiotic derived from human skin. [Emma Lewisham]
Emma Lewisham has developed what it claims to be the world-first acne serum with a live probiotic derived from human skin. [Emma Lewisham]

Related tags Acne Probiotic microbiome Skin care skin microbiome New zealand

New Zealand’s Emma Lewisham has developed what it claims to be the world-first acne serum with a live probiotic derived from human skin.

Founder and CEO Emma Lewisham said conventional acne care products tend to be harsh on the skin. For instance, many products leave skin feeling irritated and dry while reducing acne and blemishes.

“To date, most blemish and acne treatments have asked customers to make a compromise between tolerability and results,”​ said Lewisham

Lewisham told CosmeticsDesign-Asia​ that advancements in skin microbiome research motivated the development of its new acne treatment.

“We were determined to provide people with an acne and blemish treatment that not only delivered results, but that simultaneously improved the overall health and condition of the skin. Advances in research of the skin’s microbiome have highlighted the opportunity to work with our skin’s own microbial communities to deliver better solutions for blemish reduction, while improving overall skin health without harsh side effects.”

Stayin’ alive

The new serum incorporates patented Micrococcus luteus ​BLIS Q24. According to the brand, Micrococcus luteus is a highly specialised probiotic strain that naturally lives on human facial skin.

“When applied back to the skin, it delivers highly effective action against blemishes and acne. Not only this, but it also improves the health and condition of the skin by fortifying the microbiome,”​ said Lewisham.

“It is incredibly rare for cosmetic products to contain truly live probiotics so to achieve this, in addition to using a specialised skin-specific probiotic strain, is something I am very proud of and am excited for our customers to experience. This product is a wonderful example of our dedication to leading the way in scientific innovation while proving that nature is the most powerful bioengineer,” ​said Lewisham.

The product is packaged in a dual-chamber bottle that contains two formulas: the live probiotic and an activating cream.

When paired with the activating creme, the live microbes awaken, colonise on the skin, crowd out and inhibit key skin pathogens like Cutibacterium acnes.

According to the band, the Micrococcus luteus ​live skin strain probiotic is proven to stay viable for at least two years at room temperature.

Extensive probiotic stability testing has been performed in real-time, confirming that the probiotic – which remains in a dormant state in the packaging – is viable throughout this period.”

The strain It was discovered in 2004 by Professor John Tagg.

“This strain was discovered on healthy human skin and has an unparalleled capacity to impede the growth of key skin pathogens that have been found to damage human skin. By incorporating Micrococcus luteus into a skin care product, we can unlock a new and exciting level of benefits for the skin,”​ said Tagg.

Emma Lewisham secured an exclusive licence from Blis Technologies to use the cosmetic facial live probiotic serum formulation containing BLIS Q24.

The agreement allows for an exclusive license to use the cosmetic live probiotic formulation under the Emma Lewisham brand in New Zealand, Australia, and the United Kingdom.

This is Blis Technologies’ first business-to-business partnership for its skin care technology.

“We are thrilled to see the launch of our first business-to-business partnership for our skincare technology. The Emma Lewisham brand is well regarded internationally, and we look forward to supporting their growth plans with this unique product offer,” ​said Blis Technologies CEO Brian Watson.

‘Phenomenal’ trials

Emma Lewisham Supernatural Blemish Serum underwent a clinical test which resulted in “phenomenal”​ results, said Lewisham.

It was tested in vivo for 28 days twice a day. The clinical test saw a 79% reduction in the number of individuals experiencing moderate to severe blemishes.

It also recorded a 61% and 58% decline in participants experiencing blackheads and blackheads respectively.

Furthermore, a skin analysis in vivo test for 25 days reported that 90% of participants showed a measurable increase in skin hydration, while 60% of participants showed a measurable decrease in sebum.

We had overwhelming feedback about how confident people felt having clear skin, and that after using the Supernatural Blemish Serum they felt confident going out without makeup for the first time in years. I truly believe that this product has the ability to change people's lives, and nothing makes me happier than when I hear the impact it is having,​ said Lewisham.

Related news

Show more

Related products

show more

Exosomes: Passing Trend or Transformative Reality?

Exosomes: Passing Trend or Transformative Reality?

Content provided by Naolys | 23-Feb-2024 | Sponsored Link

Exosomes, microscopic vesicles naturally present in abundance within Plant Cells, have garnered significant attention within the scientific and cosmetic...

Give collagen and your products a boost

Give collagen and your products a boost

Content provided by Lycored SARL | 14-Feb-2024 | White Paper

Lumenato, Lycored’s scientifically supported proprietary wellness extract, gets to work quickly complementing and protecting the structural benefits of...

Follow us


View more


Beauty 4.0 Podcast